The Latest

Using a Precision-Medicine Platform to Address Polypharmacy in Cognitive Impairment

At the 2019 Alzheimer’s Association International Conference, July 14-18, in Los Angeles, California, uMETHOD Health shared results from an analysis that evaluated the implementation of a precision-medicine platform to create personalized, multidomain care plans for the treatment of dementia and mild Alzheimer disease. The algorithms analyze medication interactions and adverse drug reactions, such as drug-drug interactions, opioid usage, anticholinergic cognitive burden, and depression-inducing drugs, rate them using input from an open-source…READ MORE

Enhancing Medication Management Through the Use of Clinical Decision Support Software Platforms

Polypharmacy is a growing problem in the United States. The use of multiple medications increases the likelihood that a patient will experience potential drug interactions and adverse drug reactions (ADRs). Those individuals with dementia or Alzheimer’s disease (AD) are at greater risk, due to age, comorbidities, and an increased likelihood of being on a greater number of neuroactive medications. ... The results of this work show that older populations have…READ MORE

Arizona leads the way in Alzheimer’s research, new research programs announced during Alzheimer’s Awareness Month

Earlier this year the Center for Disease Control and Prevention (CDC) predicted that the burden of Alzheimer’s disease and related dementia (ADRD) in the United States is expected to double by 2060. It is predicted that Arizona has the second highest growth-rate of of Alzheimer’s disease, with cases expected to climb to 200,000 by 2025. ... Having multiple Alzheimer’s research centers & programs, some would say Arizona is at the…READ MORE

Precision-medicine platform for mild Alzheimer’s disease and at-risk individuals

Alzheimer's disease (AD) is a progressive, neurodegenerative condition in which individuals exhibit memory loss, dementia, and impaired metabolism. Nearly all previous single-domain studies to treat AD have failed, likely because it is a complex disease with multiple underlying drivers contributing to risk, onset, and progression. Keine et al. explored the efficacy of a multidomain therapy approach based on the disease risk factor status specific to individuals with AD diagnosis or…READ MORE

Alzheimer’s and AI: How Technology Can Help with Diagnosis and Treatment

Being Patient talks to Dr. John Walker, who founded uMETHOD Health, the first company that is using precision medicine and AI to help treat Alzheimer’s, about how technology could diagnose and prevent cognitive decline. To view the video, click here.…READ MORE

Sonora Quest Laboratories Partners with uMETHOD Health

Sonora Quest Laboratories, Arizona's leading provider of diagnostic testing and information services, has announced a partnership with uMETHOD Health, a health technology company offering the first platform for Alzheimer's disease based on advanced artificial intelligence technology. Through the partnership, healthcare providers will have access to the RestoreU METHOD via Sonora Quest for their patients experiencing memory loss. The platform includes lab tests and individualized care plans to assess and minimize…READ MORE

Dr. Walker featured on Healthline

Dr. John Q. Walker, uMETHOD Health's CTO, was recently quoted in an article for Healthline about a new study to help predict dementia 10 years in advance. The article covers a new Danish study that used genetics to help predict people's risk of developing dementia 10 years before they would typically be diagnosed. The study found that as we age, our risk of developing dementia or Alzheimer's disease keeps increasing. The research team…READ MORE

John Q. Walker to Speak at the Precision Medicine World Conference

Dr. John Q. Walker, uMETHOD Health co-founder and Chief Technology Officer, will be a featured speaker at the Precision Medicine World Conference held at Duke University on September 24-25, 2018. Dr. Walker's presentation, "Solving Alzheimer's," will cover the dozens of factors that contribute to Alzheimer's cognitive decline, including genetics, blood chemistry, medications, medical history, diet, and lifestyle. It will also address multi-domain interventions for this complex disease. PMWC 2018 Duke is…READ MORE

uMETHOD Health featured on is the leading online destination for those seeking information and support as they care for aging parents, spouses, and other loved ones. The site recently added a post on the link between menopause and Alzheimer’s disease. When it comes to Alzheimer’s, women are disproportionality affected, both in getting the disease as well as being the main caregiver for loved ones. The articles states that “scientists aren't sure why…READ MORE

uMETHOD Health recognized in local news

The News and Observer, a daily newspaper serving the Triangle area in Raleigh, NC, has a feature article on uMETHOD’s unique AI approach to Alzheimer’s disease. The paper is the second largest in the state and has been awarded multiple Pulitzer Prizes. Ray Gronberg wrote the article titled “Can AI give hope to Alzheimer’s patients? This Raleigh start-up says yes.” To read the full article, click here.…READ MORE